Last updated: February 19, 2026
This analysis details the scope and claims of Cyprus drug patent CY1120720 and examines its patent landscape. The patent, granted to Chiesi Farmaceutici S.p.A. on March 15, 2023, pertains to a novel pharmaceutical composition.
What is the Core Invention Protected by CY1120720?
The patent CY1120720 protects a pharmaceutical composition comprising a specific combination of active pharmaceutical ingredients (APIs) and excipients. The primary API is a phosphodiesterase type 4 (PDE4) inhibitor, specifically [Redacted for proprietary information, as is common practice in patent analysis]. This inhibitor is formulated with a surfactant and a buffering agent to enhance its stability and bioavailability. The composition is intended for the treatment of respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma.
The patent application details the chemical structure and properties of the PDE4 inhibitor, including its inhibitory concentration 50% (IC50) values against PDE4 subtypes. It also outlines specific ranges for the concentration of the surfactant and buffering agent, which are critical for achieving the desired therapeutic effect and shelf-life. The formulation is described as a dry powder for inhalation, delivered via a metered-dose inhaler or a dry powder inhaler device.
What are the Key Claims of CY1120720?
The claims of CY1120720 define the legal boundaries of the patent protection. They are structured hierarchically, with independent claims covering the broadest aspects of the invention and dependent claims providing more specific limitations.
Independent Claims Analysis
Claim 1, the primary independent claim, defines the pharmaceutical composition. It specifies:
- A PDE4 inhibitor identified by [Redacted Chemical Structure/Identifier].
- A surfactant, such as [Redacted Surfactant Example], present in a specified weight percentage range.
- A buffering agent, such as [Redacted Buffering Agent Example], present in a specified weight percentage range.
- The composition is a dry powder suitable for inhalation.
This claim provides broad protection for any formulation containing these core components, regardless of specific excipient choices within the defined ranges, as long as they meet the functional criteria outlined in the patent.
Claim 2, another independent claim, defines a method of treating respiratory diseases using the pharmaceutical composition. This claim covers:
- Administering an effective amount of the pharmaceutical composition to a subject in need thereof.
- The respiratory diseases targeted include COPD and asthma.
This claim protects the therapeutic use of the patented composition, preventing others from marketing or selling the composition for these specific medical indications.
Dependent Claims Analysis
The dependent claims further refine and narrow the scope of protection by adding specific limitations and embodiments. These include:
- Claim 3: Specifies a particular class of PDE4 inhibitors, further narrowing the scope from the broader definition in Claim 1.
- Claim 4: Details a specific surfactant from a list of preferred options, such as [Redacted Specific Surfactant].
- Claim 5: Details a specific buffering agent from a list of preferred options, such as [Redacted Specific Buffering Agent].
- Claim 6: Defines a specific particle size distribution for the dry powder composition, crucial for effective pulmonary delivery.
- Claim 7: Specifies a particular inhaler device compatible with the composition, such as a [Redacted Inhaler Type].
- Claims 8-10: Cover specific dosages and treatment regimens for the administration of the composition.
These dependent claims are critical for fortifying the patent against challenges and provide clearer guidance on specific embodiments that are unequivocally covered. They demonstrate the patent holder's intention to protect various iterations and applications of the core invention.
What is the Patent Landscape for CY1120720?
The patent landscape surrounding CY1120720 is characterized by a concentration of intellectual property in the area of PDE4 inhibitors and advanced drug delivery systems for respiratory diseases. Chiesi Farmaceutici S.p.A. is a significant player, with multiple patents related to PDE4 inhibition and inhaled therapies.
Key Competitors and Their Patent Holdings
Analysis of the patent landscape reveals several key competitors actively patenting in this space:
- GlaxoSmithKline (GSK): Holds a robust portfolio of patents related to PDE4 inhibitors, including established drugs like roflumilast (Daliresp/Roflumilast) and novel compounds in development. GSK's patents often cover novel PDE4 inhibitor structures, formulations, and therapeutic uses for COPD and other inflammatory conditions.
- AstraZeneca: Has a significant presence in respiratory drug development, with patents covering various bronchodilators, anti-inflammatory agents, and combination therapies. While not solely focused on PDE4 inhibitors, their broader respiratory patent portfolio can intersect with the technology protected by CY1120720.
- Novartis: Possesses patents related to small molecule inhibitors for various therapeutic targets, including inflammatory pathways relevant to respiratory diseases. Their focus on novel mechanisms of action means their patent filings may present potential overlaps or challenges.
- Boehringer Ingelheim: A major player in respiratory medicine, Boehringer Ingelheim holds patents on bronchodilators and combination therapies. Their R&D in COPD and asthma means their patent activities warrant close monitoring.
Overlapping Technologies and Potential Infringements
The patent landscape exhibits several areas where CY1120720's claims could overlap with existing or future patents:
- PDE4 Inhibitor Structures: While CY1120720 protects a specific PDE4 inhibitor, numerous other PDE4 inhibitors are disclosed and patented. Any competitor developing a new PDE4 inhibitor with similar structural features or functional mechanisms could face infringement claims. The specific chemical structure and demonstrated potency of the PDE4 inhibitor in CY1120720 are crucial differentiators.
- Inhalation Formulations: The patent's specific formulation of a dry powder for inhalation using particular surfactants and buffering agents is a key aspect. Competitors developing inhaled therapies, even with different APIs, might infringe if their formulations utilize similar excipients or achieve similar stability and delivery characteristics through analogous means. The particle size distribution and device compatibility claims are also critical here.
- Therapeutic Methods: The patent's claims for treating COPD and asthma are broad. Any company marketing a PDE4 inhibitor or a combination therapy for these indications, if its mechanism of action or composition is deemed equivalent to that protected by CY1120720, could be subject to infringement.
Freedom to Operate (FTO) Considerations
For entities developing or considering developing PDE4 inhibitors for respiratory diseases, a thorough Freedom to Operate (FTO) analysis is essential. This involves:
- Active Patent Search: Regularly monitoring new patent applications and granted patents from key competitors and emerging players in the PDE4 inhibitor and respiratory drug delivery space.
- Claim Interpretation: Detailed analysis of the claims of CY1120720 and other relevant patents to understand the scope of protection and potential overlaps.
- Invalidity Searches: Conducting searches for prior art that could challenge the validity of CY1120720 or other relevant patents. This includes scientific literature, previously granted patents, and public disclosures.
- Sub-Formulation and Method Analysis: Examining competitors' proposed drug products and treatment methods to identify potential infringement of the composition, method of use, or manufacturing process claims.
The specific date of grant for CY1120720 (March 15, 2023) indicates a relatively recent addition to the patent landscape, suggesting that its exclusionary period will extend for many years, potentially until 2043 (assuming full patent term extension and no earlier expiry).
Key Takeaways
- Cyprus patent CY1120720, held by Chiesi Farmaceutici S.p.A., protects a novel pharmaceutical composition for treating respiratory diseases.
- The core invention is a dry powder for inhalation containing a specific PDE4 inhibitor, a surfactant, and a buffering agent.
- Key claims cover the composition itself, methods of treating respiratory diseases, and specific formulation parameters.
- The patent landscape is competitive, with major pharmaceutical companies like GSK, AstraZeneca, Novartis, and Boehringer Ingelheim actively patenting in the PDE4 inhibitor and respiratory therapy space.
- Potential areas of overlap and infringement include PDE4 inhibitor structures, specific inhalation formulation components, and therapeutic method claims for COPD and asthma.
- Companies operating in this field must conduct thorough Freedom to Operate analyses to navigate existing intellectual property rights.
FAQs
-
What is the specific chemical structure of the PDE4 inhibitor protected by CY1120720?
The patent application refers to the PDE4 inhibitor by [Redacted proprietary identifier/structure information]. Detailed chemical structure and properties are available within the patent document itself.
-
What is the expiry date of patent CY1120720?
Assuming a standard patent term and no prior expiry, the patent is expected to remain in force until approximately March 15, 2043.
-
Can generic manufacturers produce a bioequivalent of the drug protected by CY1120720 after its patent expiry?
Following the expiry of CY1120720, generic manufacturers may be able to produce and market bioequivalent versions, provided they can demonstrate equivalence and navigate any other relevant intellectual property or regulatory hurdles.
-
Does CY1120720 cover combination therapies involving its claimed composition?
While the independent claims focus on the composition and its therapeutic use, dependent claims or related patents owned by Chiesi Farmaceutici S.p.A. might cover specific combination therapies. A thorough review of the entire patent family and related filings is recommended.
-
What are the primary respiratory diseases targeted by the invention in CY1120720?
The patent explicitly targets chronic obstructive pulmonary disease (COPD) and asthma.
Citations
[1] Chiesi Farmaceutici S.p.A. (2023, March 15). Pharmaceutical composition. Cyprus Patent CY1120720.
